Wordt geladen...
Study Progression on Non-small Cell Lung Cancer with EGFR Mutation Treated by Immune Checkpoint Inhibitors
In recent years, epidermal growth factor receptor tyrosine kinase inhibitors have been recommended by many guidelines as first-line drugs for advanced non-small cell lung cancer (NSCLC) with EGFR gene mutations and no resistance. However, with the prolongation of medication time, most appear acquire...
Bewaard in:
| Hoofdauteurs: | , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Chinês |
| Gepubliceerd in: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2018-08-01
|
| Reeks: | Chinese Journal of Lung Cancer |
| Onderwerpen: | |
| Online toegang: | http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.11 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|